Article info
Short report
Rituximab in the treatment of three coexistent neurological autoimmune diseases: chronic inflammatory demyelinating polyradiculoneuropathy, Morvan syndrome and myasthenia gravis
- Correspondence to Dr Michael P T Lunn, National Hospital for Neurology and Neurosurgery, Queen Square, London WC1N 3BG, UK; michael.lunn{at}uclh.org
Citation
Rituximab in the treatment of three coexistent neurological autoimmune diseases: chronic inflammatory demyelinating polyradiculoneuropathy, Morvan syndrome and myasthenia gravis
Publication history
- Received May 4, 2009
- Revised August 12, 2009
- Accepted August 27, 2009
- First published May 12, 2010.
Online issue publication
April 13, 2016
Article Versions
- Previous version (13 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2011, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.